2 completed, 2 not yet recruiting, 2 recruiting. 3 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Recruiting 1 |
Follow Transplantation, Stem Cell: new trials by email Literature Review of Transplantation, Stem Cell trials Research Report on Transplantation, Stem Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped mBUCY, mBUCY conditioning Regimen Group - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 180 | 2026-06-01 | 2026-06-10 |
| SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 160 | 2026-06-01 | 2026-05-01 |
| Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever Early antibiotic cessation alert - Leukemia, CART Therapy | Not applicable | Recruiting | Peter MacCallum Cancer Centre, Australia | 214 | 2025-12-03 | 2025-12-15 |
| Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia TmBU conditioning Regimen, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 48 | 2025-01-30 | 2026-04-23 |
| Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret) Ronacaleret 100 mg, Ronacaleret 400 mg, Plerixafor - Transplantation, Stem Cell | Phase 1 | Completed | GlaxoSmithKline | 24 | 2012-11-02 | 2017-06-07 |
| Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation GM-CSF, Rituximab, NK Cell Infusion - Lymphoma, Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 6 | 2006-09-01 | 2019-07-31 |
Leukemia, Myeloid, Acute (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia (2) · Bacterial Infections (1) · Febrile Neutropenia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Leukemia (3) · Leukemia, Myeloid (3) · Agranulocytosis (1) · Bacterial Infections and Mycoses (1) · Chronic Disease (1) · Cytopenia (1)
Control Groups (2) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Rituximab (1) · plerixafor (1) · ronacaleret (1) · sargramostim (1)
The First Affiliated Hospital of Soochow University (3) · GlaxoSmithKline (1) · M.D. Anderson Cancer Center (1) · Peter MacCallum Cancer Centre, Australia (1)
China (3) · United States (2) · Australia (1)
Abby P Douglas, MBBS PhD FRACP (1) · Issa F. Khouri, MD (1) · Sheng-Li Xue, M.D. (1)